These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 21748710)

  • 1. [Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain].
    Sánchez-De la Rosa R; Sabater E; Casado MA
    Rev Neurol; 2011 Aug; 53(3):129-38. PubMed ID: 21748710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.
    Chilcott J; McCabe C; Tappenden P; O'Hagan A; Cooper NJ; Abrams K; Claxton K; Miller DH;
    BMJ; 2003 Mar; 326(7388):522; discussion 522. PubMed ID: 12623909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.
    Sánchez-de la Rosa R; García-Bujalance L; Meca-Lallana J
    Health Econ Rev; 2015 Dec; 5(1):30. PubMed ID: 26475277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study.
    Souza KM; Diniz IM; Lemos LLP; Junior NGR; Zuppo IF; Teodoro JA; Acurcio FA; Atallah ÁN; Júnior AAG
    PLoS One; 2020; 15(9):e0238476. PubMed ID: 32877451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain].
    Sanz-Granda A; Garcia-Jurado L; Polanco-Sanchez C
    Rev Neurol; 2012 Apr; 54(7):446-7; author reply 447-8. PubMed ID: 22451133
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
    Darbà J; Kaskens L; Sánchez-de la Rosa R
    J Med Econ; 2014 Mar; 17(3):215-22. PubMed ID: 24494728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.
    Nikfar S; Kebriaeezadeh A; Dinarvand R; Abdollahi M; Sahraian MA; Henry D; Akbari Sari A
    Daru; 2013 Jun; 21(1):50. PubMed ID: 23800250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden.
    Fredrikson S; McLeod E; Henry N; Pitcher A; Lowin J; Cuche M; Fajutrao L; Perard R; Bates D; Chan A
    J Med Econ; 2013; 16(6):756-62. PubMed ID: 23556422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
    J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
    Sánchez-de la Rosa R; Sabater E; Casado MA; Arroyo R
    J Med Econ; 2012; 15(3):424-33. PubMed ID: 22217249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study.
    Noyes K; Bajorska A; Chappel A; Schwid SR; Mehta LR; Weinstock-Guttman B; Holloway RG; Dick AW
    Neurology; 2011 Jul; 77(4):355-63. PubMed ID: 21775734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness analysis of Avonex and CinnoVex in Relapsing Remitting MS.
    Najafi B; Ghaderi H; Jafari M; Najafi S; Ahmad Kiadaliri A
    Glob J Health Sci; 2014 Oct; 7(2):139-47. PubMed ID: 25716386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K; Meyer K; Stafkey-Mailey D; Watson C
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.
    Zhang X; Hay JW; Niu X
    CNS Drugs; 2015 Jan; 29(1):71-81. PubMed ID: 25326785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
    Sabanov AV; Luneva AV; Matveev NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(5):65-9. PubMed ID: 24988963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive cost-effectiveness analysis of treatments for multiple sclerosis.
    Newton AN; Stica CM
    Int J MS Care; 2011; 13(3):128-35. PubMed ID: 24453716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran.
    Imani A; Golestani M
    Iran J Neurol; 2012; 11(3):87-90. PubMed ID: 24250871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD; McQueen RB; Miravalle A; Corboy JR; Vollmer TL; Nair K
    Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.
    Dembek C; White LA; Quach J; Szkurhan A; Rashid N; Blasco MR
    Eur J Health Econ; 2014 May; 15(4):353-62. PubMed ID: 23615954
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.